Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kaiser Permanente
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic kidney disease
Age: \>18yo
Stable Hemoglobin (Hgb) for 1 month on stable dose of erythropoietin for 1 month (defined as erythropoietin dose within 15% of previous months erythropoietin dose)
Unchanged maintenance oral or intravenous (IV) iron therapy for 1 month
Serum 25-hydroxy Vitamin D levels \< 30 ng/mL
History of 25-hydroxy Vitamin D levels \< 30 ng/mL currently on ergocalciferol replacement
You may not be if
On hemodialysis
Chronic kidney disease 5
Hypercalcemic (Calcium level \> 11mg/dL)
Pregnant female
Iron deficient (iron saturation \< 20%, Ferritin \< 100ng/mL)
Presence of active malignancy
Presence of active infections
Presence of active inflammatory properties
Presence of blood dyscrasias
Active bleeding or bleeding within the past 3 months (other than menses)
B12 deficiency
Folate deficiency
Blood transfusion during participation
Parathyroid levels exceeding the expected levels allowed for the stage of a subjects Chronic kidney disease (Target Parathyroid in: Chronic kidney disease 3 35-70 pg/mL, Chronic kidney disease 4 70-110 pg/mL)
Clareo Health | Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose
